PURPOSE: Given evidence from randomized trials that have established the non-inferiority of more convenient and less costly courses of hypofractionated radiotherapy to the whole breast in selected breast cancer patients who receive lumpectomy, we sought to investigate the use of hypofractionated radiation therapy and factors associated with its use in a consortium of radiation oncology practices in Michigan. We sought to determine the extent to which variation in use occurs at the physician or practice level versus the extent to which use reflects individualization based on potentially relevant patient characteristics (such as habitus, age, chemotherapy receipt, or laterality). METHODS AND MATERIALS: We evaluated associations between receipt of hypofractionated radiation therapy and various patient, provider, and practice characteristics in a multilevel model. RESULTS: Of 1477 patients who received lumpectomy and whole-breast radiation therapy and were registered by the Michigan Radiation Oncology Quality Consortium (MROQC) from October 2011 to December 2013, 913 had T1-2, N0 breast cancer. Of these 913, 283 (31%) received hypofractionated radiation therapy. Among the 13 practices, hypofractionated radiation therapy use ranged from 2% to 80%. On multilevel analysis, 51% of the variation in the rate of hypofractionation was attributable to the practice level, 21% to the provider level, and 28% to the patient level. On multivariable analysis, hypofractionation was more likely in patients who were older (odds ratio [OR] 2.16 for age ≥50 years, P=.007), less likely in those with larger body habitus (OR 0.52 if separation between tangent entry and exit ≥25 cm, P=.002), and more likely without chemotherapy receipt (OR 3.82, P<.001). Hypofractionation use was not higher in the last 6 months analyzed: 79 of 252 (31%) from June 2013 to December 2013 and 204 of 661 (31%) from October 2011 to May 2013 (P=.9). CONCLUSIONS: Hypofractionated regimens of whole-breast radiation therapy have been variably administered in the adjuvant setting in Michigan after the publication of long-term trial results and consensus guidelines. Most of this variability is explained at the practice and provider level rather than by patient-level features, although care is being individualized to some degree.
PURPOSE: Given evidence from randomized trials that have established the non-inferiority of more convenient and less costly courses of hypofractionated radiotherapy to the whole breast in selected breast cancerpatients who receive lumpectomy, we sought to investigate the use of hypofractionated radiation therapy and factors associated with its use in a consortium of radiation oncology practices in Michigan. We sought to determine the extent to which variation in use occurs at the physician or practice level versus the extent to which use reflects individualization based on potentially relevant patient characteristics (such as habitus, age, chemotherapy receipt, or laterality). METHODS AND MATERIALS: We evaluated associations between receipt of hypofractionated radiation therapy and various patient, provider, and practice characteristics in a multilevel model. RESULTS: Of 1477 patients who received lumpectomy and whole-breast radiation therapy and were registered by the Michigan Radiation Oncology Quality Consortium (MROQC) from October 2011 to December 2013, 913 had T1-2, N0 breast cancer. Of these 913, 283 (31%) received hypofractionated radiation therapy. Among the 13 practices, hypofractionated radiation therapy use ranged from 2% to 80%. On multilevel analysis, 51% of the variation in the rate of hypofractionation was attributable to the practice level, 21% to the provider level, and 28% to the patient level. On multivariable analysis, hypofractionation was more likely in patients who were older (odds ratio [OR] 2.16 for age ≥50 years, P=.007), less likely in those with larger body habitus (OR 0.52 if separation between tangent entry and exit ≥25 cm, P=.002), and more likely without chemotherapy receipt (OR 3.82, P<.001). Hypofractionation use was not higher in the last 6 months analyzed: 79 of 252 (31%) from June 2013 to December 2013 and 204 of 661 (31%) from October 2011 to May 2013 (P=.9). CONCLUSIONS: Hypofractionated regimens of whole-breast radiation therapy have been variably administered in the adjuvant setting in Michigan after the publication of long-term trial results and consensus guidelines. Most of this variability is explained at the practice and provider level rather than by patient-level features, although care is being individualized to some degree.
Authors: Hely Shah; Julian Surujballi; Arif Ali Awan; Brian Hutton; Angel Arnaout; Risa Shorr; Lisa Vandermeer; Mashari Jemaan Alzahrani; Mark Clemons Journal: Breast Cancer Res Treat Date: 2020-11-06 Impact factor: 4.872
Authors: Payal D Soni; Philip S Boonstra; Matthew J Schipper; Latifa Bazzi; Robert T Dess; Martha M Matuszak; Feng-Ming Kong; James A Hayman; Randall K Ten Haken; Theodore S Lawrence; Gregory P Kalemkerian; Shruti Jolly Journal: J Thorac Oncol Date: 2017-02-01 Impact factor: 15.609
Authors: Simona F Shaitelman; Pamela J Schlembach; Isidora Arzu; Matthew Ballo; Elizabeth S Bloom; Daniel Buchholz; Gregory M Chronowski; Tomas Dvorak; Emily Grade; Karen E Hoffman; Patrick Kelly; Michelle Ludwig; George H Perkins; Valerie Reed; Shalin Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Joe Ensor; Donald Baumann; Alastair M Thompson; Diana Amaya; Tanisha Davis; William Guerra; Lois Hamblin; Gabriel Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith Journal: JAMA Oncol Date: 2015-10 Impact factor: 31.777
Authors: Simona F Shaitelman; Xiudong Lei; Alastair Thompson; Pamela Schlembach; Elizabeth S Bloom; Isidora Y Arzu; Daniel Buchholz; Gregory Chronowski; Tomas Dvorak; Emily Grade; Karen Hoffman; George Perkins; Valerie K Reed; Shalin J Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Diana N Amaya; Yu Shen; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith Journal: J Clin Oncol Date: 2018-10-31 Impact factor: 44.544
Authors: Ravi B Parikh; Justin E Bekelman; Qian Huang; Joseph R Martinez; Ezekiel J Emanuel; Amol S Navathe Journal: J Oncol Pract Date: 2019-08-08 Impact factor: 3.714
Authors: Charles S Mayo; Martha M Matuszak; Matthew J Schipper; Shruti Jolly; James A Hayman; Randall K Ten Haken Journal: Front Oncol Date: 2017-08-31 Impact factor: 6.244
Authors: Jeffrey Landercasper; Lisa Bailey; Tiffany S Berry; Robert R Buras; Amy C Degnim; Oluwadamilola M Fayanju; Joshua Froman; Jennifer Gass; Caprice Greenberg; Starr Koslow Mautner; Helen Krontiras; Roshni Rao; Michelle Sowden; Judy A Tjoe; Barbara Wexelman; Lee Wilke; Steven L Chen Journal: Ann Surg Oncol Date: 2016-06-22 Impact factor: 5.344
Authors: Joshua R Niska; Sameer R Keole; Barbara A Pockaj; Michele Y Halyard; Samir H Patel; Donald W Northfelt; Richard J Gray; Nabil Wasif; Carlos E Vargas; William W Wong Journal: Breast Cancer (Dove Med Press) Date: 2018-02-09